Literature DB >> 9601130

The Gordon Wilson Lecture. Growth hormone replacement in adults and other uses.

M L Vance1.   

Abstract

The modern era of growth hormone research began in 1981 with the characterization and synthesis of the primary stimulator of GH synthesis and secretion, growth hormone releasing hormone. Discovery of this peptide and studies in human adults and children resulted in unraveling the complex nature of the regulation of GH secretion. Discovery of regulatory mechanisms has permitted a greater understanding of normal and abnormal growth hormone physiology. The use of growth hormone therapeutically as replacement in GH deficient adults is in its medical infancy, but preliminary studies indicate a beneficial effect on body composition, serum lipid concentrations, bone mineral density, muscle strength, and exercise endurance. These studies over the past decade resulted in Food and Drug Administration approval of GH for replacement in adults with hypothalamic or pituitary disease. It remains to be determined whether or not chronic GH replacement will have beneficial effects on morbidity and mortality. The use of growth hormone in other areas such as aging, catabolic illness, obesity, diabetes, and muscular disorders is under active investigation and risks and benefits remain to be determined.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9601130      PMCID: PMC2194327     

Source DB:  PubMed          Journal:  Trans Am Clin Climatol Assoc        ISSN: 0065-7778


  32 in total

1.  Growth hormone content of pituitaries from rats with hypothalamic lesions.

Authors:  S REICHLIN
Journal:  Endocrinology       Date:  1961-08       Impact factor: 4.736

2.  The effect of intravenous, subcutaneous, and intranasal GH-RH analog, [Nle27]GHRH(1-29)-NH2, on growth hormone secretion in normal men: dose-response relationships.

Authors:  M L Vance; W S Evans; D L Kaiser; R L Burke; J Rivier; W Vale; M O Thorner
Journal:  Clin Pharmacol Ther       Date:  1986-12       Impact factor: 6.875

3.  Characterization of a growth hormone-releasing factor from a human pancreatic islet tumour.

Authors:  J Rivier; J Spiess; M Thorner; W Vale
Journal:  Nature       Date:  1982-11-18       Impact factor: 49.962

4.  Adult growth hormone (GH)-deficient patients demonstrate heterogeneity between childhood onset and adult onset before and during human GH treatment. Adult Growth Hormone Deficiency Study Group.

Authors:  A F Attanasio; S W Lamberts; A M Matranga; M A Birkett; P C Bates; N K Valk; J Hilsted; B A Bengtsson; C J Strasburger
Journal:  J Clin Endocrinol Metab       Date:  1997-01       Impact factor: 5.958

5.  Metabolic clearance and plasma disappearance rates of human pancreatic tumor growth hormone releasing factor in man.

Authors:  L A Frohman; J L Thominet; C B Webb; M L Vance; H Uderman; J Rivier; W Vale; M O Thorner
Journal:  J Clin Invest       Date:  1984-05       Impact factor: 14.808

6.  Pulsatile growth hormone secretion in normal man during a continuous 24-hour infusion of human growth hormone releasing factor (1-40). Evidence for intermittent somatostatin secretion.

Authors:  M L Vance; D L Kaiser; W S Evans; R Furlanetto; W Vale; J Rivier; M O Thorner
Journal:  J Clin Invest       Date:  1985-05       Impact factor: 14.808

7.  Human pancreatic growth-hormone-releasing factor selectively stimulates growth-hormone secretion in man.

Authors:  M O Thorner; J Rivier; J Spiess; J L Borges; M L Vance; S R Bloom; A D Rogol; M J Cronin; D L Kaiser; W S Evans; J D Webster; R M MacLeod; W Vale
Journal:  Lancet       Date:  1983-01-01       Impact factor: 79.321

8.  Growth hormone-releasing factor from a human pancreatic tumor that caused acromegaly.

Authors:  R Guillemin; P Brazeau; P Böhlen; F Esch; N Ling; W B Wehrenberg
Journal:  Science       Date:  1982-11-05       Impact factor: 47.728

9.  Effects of intravenous, subcutaneous, and intranasal administration of growth hormone (GH)-releasing hormone-40 on serum GH concentrations in normal men.

Authors:  W S Evans; M L Vance; D L Kaiser; R P Sellers; J L Borges; T R Downs; L A Frohman; J Rivier; W Vale; M O Thorner
Journal:  J Clin Endocrinol Metab       Date:  1985-11       Impact factor: 5.958

10.  Acceleration of growth in two children treated with human growth hormone-releasing factor.

Authors:  M O Thorner; J Reschke; J Chitwood; A D Rogol; R Furlanetto; J Rivier; W Vale; R M Blizzard
Journal:  N Engl J Med       Date:  1985-01-03       Impact factor: 91.245

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.